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treatments, of ?8 weeks duration were analyzed using a mixed treatment com-
parison. Bayesian hierarchical models were used to investigate three endpoints: 
lung function as assessed by forced expiratory volume in one second (FEV1) (n=28 
studies), annual moderate/severe exacerbation rate among patients with his-
tory of COPD exacerbations (n=15), and health status as assessed by St. George’s 
Respiratory Questionnaire (SGRQ) Total score (n=20). We compared ICS/LABA dos-
ages licensed in Europe, and report findings from comparisons of once-daily FF/VI 
92/22mcg with twice-daily fluticasone propionate (FP)/salmeterol (SAL) 500/50mcg 
and budesonide (BUD)/formoterol (FORM) 400/12mcg. Results: For FEV1, based 
on a 50mL delta, FF/VI demonstrated >99% probability of non-inferiority to FP/
SAL and BUD/FORM. On exacerbations, using a 10% event rate ratio delta, FF/VI 
demonstrated 73% probability of non-inferiority to FP/SAL and a 77% probability of 
non-inferiority to BUD/FORM. On SGRQ health status questionnaire scores, using 
a 2-unit delta, FF/VI demonstrated 99% probability of non-inferiority to FP/SAL 
and 98% probability of non-inferiority to BUD/FORM. Covariate effects of age and 
study duration were observed to impact on response for FEV1 and exacerbation 
rates, but not SGRQ. ConClusions: Our findings suggest that once-daily FF/VI 
has comparable efficacy with established twice-daily combination therapies in 
COPD. Key limitations include weak/disconnected treatment networks and sus-
ceptibility of the results to study inclusion criteria.
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objeCtives: Schizophrenia patients have noticeably higher smoking rates, higher 
nicotine dependence levels as well as lower smoking cessation rates compared to 
the general population. The objective of this study was to summarize the current 
evidence for efficacy of smoking cessation medications (nicotine replacement ther-
apy, Bupropion SR, or Varenicline) as treatments for nicotine dependence in patients 
with schizophrenia. Methods: A similar Cochrane review and searching terms was 
published in 2010 but no study with Varenicline was available at that time because 
of its more recent FDA approval. Consequently, we first conducted a search for rand-
omized controlled trials of NRT, Bupropion SR, or Varenicline in adult smokers with 
schizophrenia that was published after 2010. Studies were searched with Medline 
(Ovid), PubMed (National Library of Medicine), Embase (Ovid), and PsycINFO (Ovid). 
Definition of abstinence was 8-14 weeks after the cessation treatment starts. Only 
studies with abstinence measured within this range were included. Studies were 
then combined together with the studies in Cocharne review with similar outcome 
definition. Results: Seven original studies were included in this review (1 for NRT, 
4 for Bupropion SR, and 2 for Varenicline). Majority of the medications achieved 
smoking cessation with a higher percentage as compared to placebo but most of 
the effects were not statistically significant. No significant changes in mental states 
were observed after the cessation treatments exposure. ConClusions: Our review 
showed that most of the cessation medications slightly improved abstinence rates 
compared to placebo after 8 - 14 weeks of treatment, but this did not reach statisti-
cal significance. Only seven original studies were included due to limited available 
randomized controlled trials. Future studies could consider smoking reduction as 
an outcome as reaching abstinence might be difficult to achieve among schizo-
phrenia patients.
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objeCtives: Patient-reported symptoms of chronic obstructive pulmonary dis-
ease (COPD) provide important supporting information about how patients feel 
and function in addition to objective measures of pulmonary function. This analy-
sis characterized the symptom response profiles of patients with moderate to 
severe COPD who initiated treatment with arformoterol or placebo. Methods: 
Data for this post-hoc analysis came from a large, randomized, double-blind, 
safety trial of nebulized arformoterol 15µg BID (n= 420) or matched placebo 
(n= 421). Treatment with other non-long-acting beta agonists was permitted. 
This post-hoc analysis examined changes in the symptoms subscale of the St. 
George’s Respiratory Questionnaire (SGRQ). Growth Mixture Modeling (GMM) 
examined variability in individual responses over the 12-month study period 
and identified latent classes of differential responders conditional on treatment. 
Follow-up analyses characterized the baseline and treatment outcome profiles 
for the different latent classes. Results: The symptom score response profiles 
were best explained by two latent classes that were labeled “responders” and 
“non-responders.” Relative to “non-responders” (n= 259), “responders” (n= 571) 
were lower in age (63.0 vs. 65.1), more likely to smoke (55.5% vs. 44.0%), had 
more severe baseline symptoms score (75.4 vs. 46.0), and lower forced expira-
tory volume (liters) in one second (FEV1; 1.16 vs. 1.23). Responders had signifi-
cantly greater improvements in symptoms (-8.8 vs. -1.6), but not in FEV1 (0.05 
vs. 0.03). Among the responders, those treated with arformoterol had compara-
ble improvements in symptoms (-10.3 vs. -7.2, p> 0.05) and a similar number of 
exacerbations (0.55 vs. 0.69, p> 0.05), but significantly greater improvements in 
FEV1 (0.09 vs. 0.008, p= 0.03) and significantly fewer hospitalizations (0.13 vs. 0.24, 
p= 0.02). ConClusions: In this analysis, symptom response profiles were best 
explained by two latent classes. Among the responders, arformoterol appeared 
to improved lung function and reduce hospitalizations. Arformoterol may be 
particularly effective among patients who are unable to quit smoking and have 
more severe symptoms.
PHY/MI. Musculoskeletal disorders were the most prevalent inflammation-related 
condition. Multinomial logistic regression revealed that women compared to 
men (AOR: 1.88; 95% CI:1.75, 2.01); older adults (55-64 years) compared to younger 
adults (18-24 years) had significantly higher likelihood (AOR: 6.14; 95% CI:5.05, 
7.04) of having IF_PHY/MI. Interestingly, African Americans, Hispanics and Asians 
had lower likelihood of having IF_PHY/MI compared to Whites. ConClusions: 
High prevalence of inflammation-related multimorbidity among individuals with 
COPD warrant the need for clinical practice guidelines for evidence-based man-
agement.
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objeCtives: To evaluate the relationship between asthma-related health care 
utilization with two different types of asthma treatments (inhaled Fluticasone 
Propionate (FP) and fixed dose combination of Fluticasone Propionate and 
Salmeterol (FPS)) among a commercially insured adolescent and adult popula-
tion. Methods: This retrospective cohort study used propensity-score matching 
to identify patients in a large nationally representative administrative claims 
database. The sample consisted of patients aged 12 to 64 who had a new prescrip-
tion fill (index) for FP or FPS after asthma diagnosis (ICD-9-CM 493.XX) between 
2006 and 2012. Patients were continuously enrolled in a plan with pharmacy and 
medical coverage for at least 12 months before and after treatment initiation. 
Patients were excluded if they: (a) used FP or FPS within 90 days prior to index; (b) 
had a diagnosis of chronic obstructive pulmonary disease (ICD-9-CM 490.XX-492.
XX, 494.XX, 496.XX); or (c) used other asthma controller medications after index. 
Eligible patients were followed up to 12 months after initiation. A multivariate 
logistic regression model was used to observe the association between asthma-
related health care utilization in the two cohorts. Results: The study popula-
tion included 8,059 patients treated with FP (female= 57.0%, average age= 33.9 (± 
17.6), hospitalization rate= 1.4%, ED rate= 5.0%) and 8,059 patients treated with FPS 
(female= 57.5%, average age= 33.9 (± 17.4), hospitalization rate= 1.8%, ED rate= 5.5%). 
The multivariate logistic regression model revealed FPS users had no significant 
difference in likelihood of asthma-related hospitalizations (OR= 1.26; 95% CI 0.98-
1.62, p-value= 0.0667) or ED visits (OR= 1.13; 95% CI 0.98-1.3, p-value= 0.0884) com-
pared to FP users. ConClusions: This large retrospective analysis found that 
users of FP versus FPS have statistically similar rates of asthma-related health care 
utilization at the 95% level. However, the large positive odds ratios, significant at 
the 90% level, indicate a need for additional research to investigate comparative 
effectiveness of the two therapies.
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(ff/vi) iS ComPaRable with twiCe-Daily Combination theRaPieS in 
aSthma: a mixeD tReatment ComPaRiSon
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objeCtives: To determine the relative treatment efficacy of FF/VI, a once-daily 
inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA) combination therapy, 
compared with corresponding dosages of established twice-daily ICS/LABA thera-
pies, in patients with asthma. Methods: Following a systematic literature review, 
data from 31 parallel-group randomized controlled trials, consisting of 24 different 
treatments, of >8 weeks’ duration and in patients aged ?12 years were included 
in the mixed treatment comparison. Bayesian hierarchical models were used to 
investigate four endpoints: lung function (peak expiratory flow [PEF] (n=18 studies) 
and forced expiratory volume in one second [FEV1] (n=28)), annual exacerbation 
rates (n=6), and health status (Asthma Quality of Life Questionnaire [AQLQ]) (n=7). 
We compared ICS/LABA dosages licensed in Europe, and report findings from com-
parisons of once-daily FF/VI (92/22mcg and 184/22mcg) with twice-daily fluticasone 
propionate (FP)/salmeterol (SAL) (250/50mcg and 500/50mcg) and budesonide (BUD)/
formoterol (FORM) (400/12mcg and 800/24mcg). Results: On PEF, based on a 12L/
min delta, FF/VI 92/22mcg and 184/22mcg demonstrated ?94% and >99% probability 
of non-inferiority to corresponding doses of FP/SAL and BUD/FORM, respectively. On 
FEV1, based on a 100mL threshold, FF/VI demonstrated ?99% and ?98% probability of 
non-inferiority to FP/SAL and BUD/FORM. On exacerbations, using a 10% event rate 
ratio delta, FF/VI 92/22mcg demonstrated 74% and 82% probability of non-inferiority 
to corresponding doses of FP/SAL and BUD/FORM. On AQLQ, based on a score delta 
of 0.25, FF/VI 92/22mcg demonstrated >99% and 90% probability of non-inferiority 
to FP/SAL and BUD/FORM. There were insufficient data to assess non-inferiority of 
FF/VI 184/22mcg on exacerbations or AQLQ. ConClusions:  Our findings suggest 
that once-daily FF/VI has comparable efficacy with established twice-daily combi-
nation therapies in asthma. Key limitations include weak/disconnected treatment 
networks and susceptibility of the results to study inclusion criteria.
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objeCtives: To determine the relative treatment efficacy of FF/VI 92/22mcg, a 
once-daily inhaled corticosteroid (ICS)/long-acting beta2agonist (LABA) combi-
nation therapy, compared with established twice-daily ICS/LABA therapies, in 
patients with COPD. Methods: Following a systematic literature review, data 
from 33 parallel-group randomized controlled trials, consisting of 26 different 
